EUVIMEDEUVIMED entdecken
Crossref

A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children

Subham Bhattacharya, Siddhartha Sankar Ray, Prantar Chakrabarti, Tapas Sabui, Sanjoy Kumar Sadhukhan, Maitreyee Bhattacharyya

Journal of Hematology and Allied Sciences · 2022

DOI: 10.25259/jhas_12_2021 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Hematology and Allied Sciences, 2022. Verfasst von Subham Bhattacharya und 5 weiteren Autor:innen. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 17 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

Treatment for children with newly diagnosed immune thrombocytopenia (ITP) includes corticosteroids, out of which prednisolone is commonly used. High-dose dexamethasone (HD-DXM) treatment for children with newly diagnosed ITP can produce better outcomes than prednisone, as stated by many studies. A few articles compare HD-DXM and prednisolone as frontline therapies in newly diagnosed adult ITP but data on pediatric ITP comparing these two drugs are scarce. Material and Methods: It was a randomized, prospective, and cohort study. After enrolment, checking the inclusion and exclusion criteria, each child was randomly distributed into two groups; one cohort was treated with HD-DXM in the dose of 40 mg/m 2 (maximum daily dose 40 mg) for 4 days once every 28 days for three cycles; and one with prednisolone in the dose of 2 mg/kg/day (maximum 60 mg/day) for 2 weeks, with quick tapering. A total of 42 children were enrolled, 21 in each cohort.

Results

The overall response (OR) was 42.9% with HD-DXM therapy. The OR and median time to response were similar in both HD-DXM and prednisolone cohorts. There was also no significant difference in incidences of adverse effects between the two cohorts.

Conclusion

Thus, this study confirms that HD-DXM is a safe, effective, and non-inferior option compared to prednisolone as frontline therapy in newly diagnosed ITP in children.

Zitieren

APA

Bhattacharya, S., Ray, S. S., Chakrabarti, P., Sabui, T., Sadhukhan, S. K., & Bhattacharyya, M. (2022). A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children. Journal of Hematology and Allied Sciences. https://doi.org/10.25259/jhas_12_2021

Vancouver

Bhattacharya S, Ray SS, Chakrabarti P, Sabui T, Sadhukhan SK, Bhattacharyya M. A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children. Journal of Hematology and Allied Sciences. 2022. doi:10.25259/jhas_12_2021

BibTeX
@article{Bhattacharya2022,
  author = {Bhattacharya, Subham and Ray, Siddhartha Sankar and Chakrabarti, Prantar and Sabui, Tapas and Sadhukhan, Sanjoy Kumar and Bhattacharyya, Maitreyee},
  title = {A study on high-dose dexamethasone versus prednisolone as frontline therapy in newly diagnosed immune thrombocytopenia in children},
  journal = {Journal of Hematology and Allied Sciences},
  year = {2022},
  doi = {10.25259/jhas_12_2021}
}
Kostenlos starten →